Bortezomib-Dexamethasone, Rituximab, and Cyclophosphamide as First-Line Treatment for Waldenström's Macroglobulinemia: A Prospectively Randomized Trial of the European Consortium for Waldenström's Macroglobulinemia.

Christian Buske Meletios- Athanasios DimopoulosAlexander GrunenbergEfstathios Kastritis Cécile TomowiakBéatrice MahéXavier Troussard Roman HájekAndreas ViardotOlivier TournilhacTherese AurranStephane LepretreHacene ZerazhiBenedicte HivertVeronique LeblondSophie de GuibertLena Brandefors Miriam Santero Maria Gomes da Silva Eva KimbyBirgit SchmelzleDajana KaszynskiJens DreyhauptRainer MuchePierre Morel

Published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023)

This large randomized study illustrates that B-DRC is highly effective and well tolerated in WM. The data demonstrate that fixed duration immunochemotherapy remains an important pillar in the clinical management of WM.

Keyphrases

diffuse large b cell lymphoma
high dose
low dose
multiple myeloma
electronic health record
big data
newly diagnosed
hodgkin lymphoma
chronic lymphocytic leukemia
data analysis